Insmed reported $544.86M in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Cytokinetics USD 244.33M 3.87M Sep/2026
Gilead Sciences USD 23.82B 17M Sep/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 544.86M 1.35M Sep/2026
Novartis USD 36.7B 748M Sep/2026
Regeneron Pharmaceuticals USD 1.99B 400K Sep/2026
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026